Globeimmune Inc - ESG Rating & Company Profile powered by AI
This analysis of Globeimmune Inc uses data from across the web and also from public disclosures by Globeimmune Inc. The ESG rating includes seventeen UN Sustainable Development Goals including: 'No Poverty', 'Sustainable Cities & Communities' and 'Peace, Justice & Strong Institutions'. This article includes a questions and answers table for Globeimmune Inc.
Globeimmune Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2747 | Aphria Inc | 0.3 | Low |
| 2747 | Sichuan Languang Development Co Ltd | 0.3 | Low |
| 2749 | Globeimmune Inc | 0.0 | Low |
| 2749 | Alpha Group Industries Inc | 0.0 | Low |
| 2749 | BNC Korea Co Ltd (Pre-Merger) | 0.0 | Low |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Globeimmune Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Globeimmune Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Globeimmune Inc report the average age of the workforce?
Sign up for free to unlockDoes Globeimmune Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Globeimmune Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Globeimmune Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Globeimmune Inc offer flexible work?
Sign up for free to unlockDoes Globeimmune Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Globeimmune Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Globeimmune Inc conduct supply chain audits?
Sign up for free to unlockDoes Globeimmune Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Globeimmune Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Globeimmune Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Globeimmune Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Globeimmune Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Globeimmune Inc disclose water use targets?
Sign up for free to unlockDoes Globeimmune Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Globeimmune Inc have a product recall in the last two years?
Sign up for free to unlockDoes Globeimmune Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Globeimmune Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Globeimmune Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Globeimmune Inc disclose parental leave metrics?
Sign up for free to unlockDoes Globeimmune Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Globeimmune Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Globeimmune Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Globeimmune Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Globeimmune Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Globeimmune Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Globeimmune Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Globeimmune Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Globeimmune Inc disclose its waste policy?
Sign up for free to unlockDoes Globeimmune Inc report according to TCFD requirements?
Sign up for free to unlockDoes Globeimmune Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Globeimmune Inc disclose energy use targets?
Sign up for free to unlockDoes Globeimmune Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Globeimmune Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Globeimmune Inc
These potential risks are based on the size, segment and geographies of the company.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.